Sutro Biopharma - STRO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: 201.72%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$4.64
▼ -0.07 (-1.49%)

This chart shows the closing price for STRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sutro Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for STRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for STRO

Analyst Price Target is $14.00
▲ +201.72% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is $14.00, with a high forecast of $25.00 and a low forecast of $8.00. The average price target represents a 201.72% upside from the last price of $4.64.

This chart shows the closing price for STRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 contributing investment analysts is to moderate buy stock in Sutro Biopharma. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2024WedbushReiterated RatingOutperform$12.00Low
11/15/2023Piper SandlerLower TargetOverweight ➝ Overweight$18.00 ➝ $12.00Low
11/14/2023WedbushReiterated RatingOutperform$12.00Low
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$12.00Low
10/23/2023WedbushReiterated RatingOutperform ➝ Outperform$12.00Low
10/5/2023OppenheimerInitiated CoverageOutperform$10.00Low
9/6/2023Truist FinancialReiterated RatingBuy ➝ Buy$25.00Low
8/14/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$17.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
8/11/2023WedbushLower TargetOutperform ➝ Outperform$20.00 ➝ $12.00Low
4/3/2023JMP SecuritiesLower TargetOutperform$20.00 ➝ $17.00Low
3/31/2023WedbushReiterated RatingOutperform$20.00N/A
3/31/2023HC WainwrightLower TargetBuy$20.00 ➝ $16.00Low
3/21/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $8.00Low
1/13/2023Truist FinancialBoost TargetBuy$21.00 ➝ $25.00Low
1/10/2023Piper SandlerBoost TargetOverweight$16.00 ➝ $18.00N/A
11/9/2022HC WainwrightLower TargetBuy$30.00 ➝ $20.00Low
8/23/2022Truist FinancialLower TargetBuy$37.00 ➝ $21.00Low
8/18/2022Wells Fargo & CompanyReiterated RatingOverweight$15.00Low
7/6/2022JMP SecuritiesReiterated RatingBuy$20.00N/A
7/4/2022Piper SandlerBoost Target$16.00N/A
6/28/2022Piper SandlerBoost Target$14.00 ➝ $16.00Low
6/6/2022JMP SecuritiesReiterated RatingBuy$20.00Low
5/23/2022Piper SandlerLower TargetOverweight$29.00 ➝ $14.00Low
5/11/2022HC WainwrightLower Target$35.00 ➝ $30.00High
5/10/2022WedbushLower Target$30.00 ➝ $20.00High
4/11/2022JMP SecuritiesReiterated RatingBuy$20.00High
3/7/2022JMP SecuritiesLower Target$28.00 ➝ $20.00High
1/6/2022WedbushLower Target$37.00 ➝ $30.00Low
11/17/2021Berenberg BankInitiated CoverageBuy$30.00High
10/1/2021Wells Fargo & CompanyReiterated RatingBuy$30.00Low
6/22/2021JMP SecuritiesReiterated RatingBuy$28.00High
6/18/2021HC WainwrightInitiated CoverageBuy$35.00High
1/28/2021Truist FinancialBoost Target$24.00 ➝ $37.00Medium
12/2/2020Stifel NicolausInitiated CoverageBuy$25.00Low
11/6/2020Piper SandlerBoost TargetOverweight$20.00 ➝ $22.00Low
9/2/2020Jefferies Financial GroupInitiated CoverageBuy$21.00High
7/16/2020Wells Fargo & CompanyInitiated CoverageOverweight$18.00High
5/18/2020Piper SandlerLower Target$23.00 ➝ $20.00Medium
5/13/2020HC WainwrightLower TargetBuy$18.00 ➝ $17.00Low
5/12/2020B. RileyDowngradeHoldLow
3/17/2020HC WainwrightReiterated RatingBuy$18.00High
3/16/2020CowenReiterated RatingBuyHigh
1/13/2020SunTrust BanksInitiated CoverageBuy$18.00Low
10/30/2019WedbushReiterated RatingOutperformMedium
10/21/2019HC WainwrightReiterated RatingBuy$18.00High
10/7/2019BTIG ResearchInitiated CoverageBuy$19.00High
9/5/2019JMP SecuritiesReiterated RatingMarket Outperform$16.00Medium
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$22.00High
6/24/2019HC WainwrightSet TargetBuy$18.00Low
6/16/2019CowenReiterated RatingBuyLow
5/17/2019HC WainwrightSet TargetBuy$18.00Low
5/16/2019CowenReiterated RatingBuyLow
5/7/2019HC WainwrightReiterated RatingBuy$18.00High
4/29/2019HC WainwrightInitiated CoverageBuy ➝ Buy$18.00High
3/4/2019WedbushBoost TargetOutperform$20.00 ➝ $22.00Low
(Data available from 2/22/2019 forward)

News Sentiment Rating

1.17 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/26/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/25/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/25/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/24/2023
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/23/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Sutro Biopharma logo
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $4.64
Low: $4.58
High: $4.81

50 Day Range

MA: $4.33
Low: $3.49
High: $4.99

52 Week Range

Now: $4.64
Low: $2.01
High: $6.23

Volume

402,570 shs

Average Volume

830,465 shs

Market Capitalization

$282.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Sutro Biopharma?

The following Wall Street research analysts have issued stock ratings on Sutro Biopharma in the last twelve months: Deutsche Bank Aktiengesellschaft, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, Truist Financial Co., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for STRO.

What is the current price target for Sutro Biopharma?

8 Wall Street analysts have set twelve-month price targets for Sutro Biopharma in the last year. Their average twelve-month price target is $14.00, suggesting a possible upside of 201.7%. Truist Financial Co. has the highest price target set, predicting STRO will reach $25.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $8.00 for Sutro Biopharma in the next year.
View the latest price targets for STRO.

What is the current consensus analyst rating for Sutro Biopharma?

Sutro Biopharma currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for STRO.

What other companies compete with Sutro Biopharma?

How do I contact Sutro Biopharma's investor relations team?

Sutro Biopharma's physical mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company's listed phone number is (650) 392-8412 and its investor relations email address is [email protected]. The official website for Sutro Biopharma is www.sutrobio.com. Learn More about contacing Sutro Biopharma investor relations.